Proteomics

Dataset Information

0

Phospho-proteome analysis of PBMCs in LRRK2 mutation carriers: expansion & validation of findings of the Barcelona LRRK2 Biorepository


ABSTRACT: Supported by the Michael J Fox Foundation we established a biorepository of blood cells from G2019S LRRK2-PD patients recruited at the Hospital Clínic de Barcelona (Barcelona). Using this cohort, we performed a phospho-proteomic pilot study by mass spectrometry and identified a differential combination of phosphorylated proteins associated with the G2019S mutation. Here, we aim to validate and expand these findings using additional G2019S and R1441G cohorts (PMID: 35049090 By state-of-the-art DIA phospho-proteomics we aim to validate and expand our preliminary findings in additional G2019S and R1441G LRRK2 cohorts of similar design, size, and blood cell collection methods collected at additional centers in Spain (Hospital de Valdecilla in Santander, Hospital de Donostia in San Sebastian). We expect to identify differential protein phosphorylation changes in LRRK2-PD patients affected by the G2019S and R1441G mutations that could be useful as LRRK2 pharmacodynamic biomarkers. In asymptomatic LRRK2 mutation carriers, we will explore the presence of these phosphorylation changes and evaluate their applicability as early disease biomarkers.

INSTRUMENT(S): Orbitrap Exploris 480

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Peripheral Blood Mononuclear Cell

SUBMITTER: Enrique Santamaría  

LAB HEAD: Mario Ezquerra

PROVIDER: PXD050865 | Pride | 2025-06-09

REPOSITORIES: Pride

Dataset's files

Source:
Action DRS
224_ProtTotal_20221027.sne Other
B02.raw Raw
B03.raw Raw
B04.raw Raw
B05.raw Raw
Items per page:
1 - 5 of 156
altmetric image

Publications

In-depth mass-spectrometry reveals phospho-RAB12 as a blood biomarker of G2019S LRRK2-driven Parkinson's disease.

Cortés Adriana A   Phung Toan K TK   de Mena Lorena L   Garrido Alicia A   Infante Jon J   Ruíz-Martínez Javier J   Galmés-Ordinas Miquel À MÀ   Glendinning Sophie S   Pérez Jesica J   Roig Ana A   Soto Marta M   Cosgaya Marina M   Ravasi Valeria V   Fernández Manel M   Rubiano-Castro Alejandro A   Díaz Ramón R   Hernández-Eguiazu Haizea H   Sánchez-Quintana Coro C   Vinagre-Aragón Ana A   Mondragón Elisabet E   Croitoru Ioana I   Rivera-Sánchez María M   Corrales-Pardo Andrea A   Sierra María M   Tolosa Eduardo E   Malagelada Cristina C   Nirujogi Raja S RS   Fernández-Irigoyen Joaquín J   Santamaría Enrique E   Alessi Dario R DR   Martí María J MJ   Ezquerra Mario M   Fernández-Santiago Rubén R  

Brain : a journal of neurology 20250601 6


Leucine-rich repeat kinase 2 (LRRK2) inhibition is a promising disease-modifying therapy for LRRK2-associated Parkinson's disease (L2PD) and idiopathic PD. However, pharmacodynamic readouts and progression biomarkers for clinical trials aiming for disease modification are insufficient, given that no endogenous marker reflecting enhanced kinase activity of the most common LRRK2 G2019S mutation has yet been reported in L2PD patients. Using phospho-/proteomic analyses, we assessed the impact of LRR  ...[more]

Similar Datasets

2025-06-09 | PXD050944 | Pride
2013-11-22 | GSE52584 | GEO
2021-02-27 | GSE167704 | GEO
2021-09-10 | PXD024898 | Pride
2013-11-22 | E-GEOD-52584 | biostudies-arrayexpress
2019-02-02 | GSE125234 | GEO
2018-03-07 | GSE101534 | GEO
2012-10-17 | E-GEOD-33298 | biostudies-arrayexpress
2018-07-01 | GSE90469 | GEO
2012-10-17 | E-GEOD-36321 | biostudies-arrayexpress